ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Japan Tissue Engineering Co., Ltd.

  • 960.00 JPY
  • +25.00
  • +2.67%
  • Japan
    Dec 17, 2018
  • Ticker
    JAS(7774)
  • Prev. close
    935
  • Market cap (JPY)
    37,970.53M
  • Market cap (USD)
    334.79M
  • Shares
    40.61M

Business Summary

Japan Tissue Engineering Co., Ltd. engages in the research, development, and manufacture of cultured biological cells and tissues. It operates through the Regenerative Medicine, Custom Development and Manufacturing, and Research and Development (R&D) Support segments. The Regenerative Medicine segment develops, manufactures, and sells tissue-engineered medical products through autologous culturing techniques. The Custom Development and Manufacturing segment consists of research and development, clinical development, regulatory affairs, production, quality assurance, and sales of regenerative medical products. The R&D Support segment deals with the research of cultured human tissues. The company was founded on February 1, 1999 and is headquartered in Gamagori, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue2,271.50M20.49M
Gross Profit1,294.49M11.67M
Operating income205.52M1.85M
Income before tax213.33M1.92M
Net income227.89M2.05M
EBITDA327.70M2.95M
Diluted EPS5.610.05
Dividends Per Share00
Total Assets9,023.07M84.84M
Total liabilities771.63M7.25M
Total equity8,251.43M77.58M
Operating cash flow632.00M5.70M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 1,008.04M 1,321.49M 1,430.82M 2,135.14M 2,271.50M
Gross Profit 423.26M 483.00M 506.50M 1,191.32M 1,294.49M
Operating income -1,028.12M -916.55M -952.64M 303.16M 205.52M
Income before tax -823.99M -686.68M -898.35M 309.95M 213.33M
Net income -827.83M -690.52M -681.53M 276.24M 227.89M
EBITDA -937.08M -826.67M -807.20M 425.33M 327.70M
Diluted EPS -22.54 -18.21 -16.79 6.81 5.61
Dividends Per Share 0 0 0 0 0
Total Assets 3,232.67M 8,853.18M 8,296.50M 8,546.36M 9,023.07M
Total liabilities 1,069.27M 456.07M 578.42M 541.22M 771.63M
Total equity 2,163.39M 8,397.11M 7,718.07M 8,005.14M 8,251.43M
Operating cash flow -961.31M -756.72M -346.90M 54.95M 632.00M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 10.06M 12.02M 11.91M 19.71M 20.49M
Gross Profit 4.22M 4.39M 4.21M 11.00M 11.67M
Operating income -10.26M -8.34M -7.93M 2.79M 1.85M
Income before tax -8.22M -6.25M -7.48M 2.86M 1.92M
Net income -8.26M -6.28M -5.67M 2.55M 2.05M
EBITDA -9.35M -7.52M -6.72M 3.92M 2.95M
Diluted EPS -0.22 -0.16 -0.13 0.06 0.05
Dividends Per Share 0 0 0 0 0
Total Assets 31.38M 73.82M 73.81M 76.69M 84.84M
Total liabilities 10.38M 3.80M 5.14M 4.85M 7.25M
Total equity 21.00M 70.01M 68.66M 71.84M 77.58M
Operating cash flow -9.59M -6.88M -2.88M 0.50M 5.70M

Valuation Measures

Mar 2018
PER322.10
ROA2.59%
ROE2.80%
Operating margin9.04%
Profit margin10.03%

Key executives

  • President & Representative Director: Ken-ichiro Hata
  • Executive Officer, GM-Research & Development: Masukazu Iie
  • Director & GM-Business Administration: Toshiyuki Hara
  • Executive Officer & Manager-Internal Audit: Toru Kuroda
  • Executive Officer & Senior Deputy GM-Production: Yukio Mori

Shareholders

  • FUJIFILM Holdings Corp. (50.1%)
  • Nidek Co., Ltd. (10.4%)
  • Chubushiryo Co., Ltd. (0.9%)
  • GOMI DAISUKE (0.9%)
  • MAEDA YOKO (0.8%)
  • OZAWA YOSUKE /JAPAN TISSUE ENGINEERING/ (0.7%)
  • KUWATA TAKESHI (0.6%)
  • Sala Corp. (0.4%)
  • OSUKA TOSHIHIRO (0.2%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.2%)

Contact Details

Related Companies

    Competitors

    • Histogenics Corp.
    Last Updated on 17 Dec, 2018

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Get Unlimited access

    {{sentenceStarter}} {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} this month

    Stay ahead with our exclusives on Asia; the most dynamic market in the world.

    Benefit from in-depth journalism from trusted experts within Asia itself.

    Try 3 months for $9

    Offer ends September 30th

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media